1. Nonpeptide luteinizing hormone-releasing hormone antagonists derived from erythromycin A: design, synthesis, and biological activity of cladinose replacement analogues.
- Author
-
Randolph JT, Waid P, Nichols C, Sauer D, Haviv F, Diaz G, Bammert G, Besecke LM, Segreti JA, Mohning KM, Bush EN, Wegner CD, and Greer J
- Subjects
- Administration, Oral, Animals, Cells, Cultured, Cricetinae, Drug Design, Erythromycin pharmacology, Gonadotropin-Releasing Hormone blood, Gonadotropin-Releasing Hormone metabolism, Hexoses pharmacology, Humans, Injections, Intravenous, Male, Models, Molecular, Orchiectomy, Pituitary Gland cytology, Pituitary Gland metabolism, Rats, Structure-Activity Relationship, Erythromycin analogs & derivatives, Erythromycin chemical synthesis, Gonadotropin-Releasing Hormone antagonists & inhibitors, Hexoses chemical synthesis
- Abstract
The design and synthesis of a series of 11,12-cyclic carbamate derivatives of 6-O-methylerythromycin A that are novel, nonpeptide LHRH antagonists, is described. The macrolide antagonist 1, discovered during a screen of our chemical repository, was compared to a macrocyclic peptide antagonist 2 using molecular modeling, thus providing a model for the design of more potent antagonists. Medicinal chemistry efforts to find a replacement for cladinose at position 3 of the erythronolide core provided a series of oxazolidinone carbamates that were equally as active as the cladinose-containing parent macrolides. The descladinose LHRH antagonist 14 has 1-2 nM affinity for both rat and human LHRH receptors and is a potent inhibitor of LH release (pA2 = 8.76) in vitro. In vivo, 14 was found to produce a dose-dependent suppression of LH in male castrate rats via both i.v. and p.o. dosing.
- Published
- 2004
- Full Text
- View/download PDF